Skip to main content
Caplight Logo









PEP-Therapy

PEP-Therapy

Private
ParisHealthcare & Life Scienceshttps://pep-therapy.com/

Last Round

Series A

Extension

Jul 19, 2021

Total Funding Raised

$11.27M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

PEP-Therapy is a biotechnology company that develops first-in-class peptide-based targeted therapies for oncology using an intracellular drug delivery shuttle.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologypeptide therapytargeted oncologydrug delivery platformintracellular deliverysolid tumorsdrug discoveryprecision medicineclinical trialsbiotech startuptherapeutic peptidesundruggable targetsprotein phosphatase 2APP2Adrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PEP-Therapy Comparables

Compare PEP-Therapy with similar companies based on industry and business-model similarity.

PEP-Therapy comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Sapience Therapeutics
84%
Cybrexa Therapeutics
82%
APIM Therapeutics AS
82%

PEP-Therapy Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionJul 19, 2021
Series AApr 22, 2021
GrantApr 17, 2018
SeedApr 27, 2015

Key People

Founding team and executive leadership

Antoine PRESTAT

Co-founder & CEO

Founding Team

PEP-Therapy Investors

Notable investors and investment history

PEP-Therapy investors
InvestorRounds
AnaxagoSeries A Extension
BpifranceSeries A Extension
Business Angels des Grandes EcolesSeries A Extension, Series A
Seventure PartnersSeries A
i&i PragueSeries A Extension
DoorwaySeries A
Italian Angels for GrowthSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 474% MoM.

  • Apr 6, 2026

    Monthly visitors increased 159% MoM, reaching 2.1K.

PEP-Therapy Filings

Explore SEC and related filing metadata, where available.

PEP-Therapy filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about PEP-Therapy's valuation, stock price, and market status.

Is PEP-Therapy a public or private company?

PEP-Therapy is a private company.

What is the current stock price of PEP-Therapy?

PEP-Therapy is a private company with no public stock price. No recent secondary market data is available.

How much is PEP-Therapy worth (valuation)?

Valuation information for PEP-Therapy is not publicly available.

Can I buy PEP-Therapy stock?

PEP-Therapy shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was PEP-Therapy's last funding round?

PEP-Therapy's most recent funding round was Series A Extension on July 19, 2021.

Who are the main investors in PEP-Therapy?

Key investors in PEP-Therapy include Italian Angels for Growth.

Will PEP-Therapy IPO soon?

No public IPO plans have been announced for PEP-Therapy.

How can I track PEP-Therapy secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor PEP-Therapy's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersParis
Employee Range10
Year Founded2014
Last FundingJul 19, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?